Login to Your Account

Pharma: Other News To Note

Monday, December 2, 2013
• Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA granted orphan drug exclusivity for Treanda (bendamustine) through October 2015 for indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) or a rituximab-containing regimen.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription